{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.8","upperLimit":"70.1","value":"43.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"description":"Participants who achieved remission (CR/CRh\\*) during the first 2 cycles of treatment and received an allogeneic HSCT.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for 2 cycles. Participants who achieved a complete remission or complete remission with partial or incomplete hematologic recovery within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.\n\nThe initial dose was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 and for all subsequent cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Participants who received an infusion of blinatumomab and had a CR/CRh\\* response during the first 2 cycles of treatment.","reportingStatus":"POSTED","timeFrame":"Up to the data cut-of date of 20 May 2015; Maximum duration on study was 14.5 months.","title":"Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission","type":"SECONDARY","unitOfMeasure":"percentage of participants"}